Valuation : Cerus Corporation

Market Cap 52Cr 45Cr 42Cr 38Cr 72Cr 4.89TCr 72Cr 495.49Cr 192.27Cr 2.51TCr 194.48Cr 190.24Cr 8.08TCr P/E 2026 *
-73.4x
P/E 2027 * -257x
Enterprise Value 52Cr 45Cr 42Cr 39Cr 72Cr 4.94TCr 73Cr 500.27Cr 194.13Cr 2.53TCr 196.36Cr 192.08Cr 8.16TCr EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.86x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week-2.26%
Current month-1.89%
1 month+18.26%
3 months-7.17%
6 months+15.62%
Current year+25.73%
1 week 2.52
Extreme 2.5209
2.69
1 month 2.13
Extreme 2.13
3.08
Current year 1.62
Extreme 1.62
3.47
1 year 1.17
Extreme 1.17
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-30,000 0.0150%
16/07/26 Sell

Chief Executive Officer

-16,666 0.0083%
01/07/26 Free

Chief Executive Officer

9,24,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-2.26%+94.74%+48.00% 52Cr
-1.58%-8.33%-23.13%+5.88% 12TCr
+1.14%-0.79%-23.40%-0.05% 1.2TCr
-1.60%-1.33%+96.88%+141.19% 1.06TCr
+2.47%-0.35%-50.14%-70.18% 409.33Cr
+0.10%-9.15%-24.37%+36.17% 247.81Cr
-1.76%-6.83% - - 197.34Cr
+1.51%+2.67%-26.92%-73.08% 179.65Cr
+0.67%-4.14%-19.33%-24.68% 155.56Cr
Average +0.18%-1.82%+3.04%+7.91% 1.7TCr
Weighted average by Cap. -1.18%-3.65%-15.06%+12.26%

Financials

2026 *2027 *
Net sales 25Cr 21Cr 20Cr 18Cr 34Cr 2.35TCr 35Cr 238.26Cr 92Cr 1.21TCr 94Cr 91Cr 3.89TCr 27Cr 23Cr 22Cr 20Cr 38Cr 2.56TCr 38Cr 259.77Cr 100.8Cr 1.32TCr 101.96Cr 100Cr 4.24TCr
Net income -87.67L -75.44L -70.98L -64.84L -1.21Cr -83Cr -1.22Cr -8.39Cr -3.25Cr -42Cr -3.29Cr -3.22Cr -136.81Cr -16.67L -14.34L -13.49L -12.33L -23.06L -16Cr -23.12L -1.59Cr -61.87L -8.07Cr -62.59L -61.22L -26Cr
Net Debt 50L 43.02L 40.48L 36.98L 69.18L 47Cr 69.36L 4.78Cr 1.86Cr 24Cr 1.88Cr 1.84Cr 78Cr -1.3Cr -1.12Cr -1.05Cr -96.15L -1.8Cr -122.74Cr -1.8Cr -12Cr -4.83Cr -63Cr -4.88Cr -4.78Cr -202.87Cr
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
05/26/05 $2.590 +0.78% 11,02,510
03/26/03 $2.570 -1.15% 9,17,117
02/26/02 $2.600 -0.38% 15,74,953
01/26/01 $2.610 -1.14% 10,83,876
31/26/31 $2.640 -0.38% 13,21,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.570USD
Average target price
5.125USD
Spread / Average Target
+99.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock